Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jon Thor Asmussen

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 13, 2021
Evolution of the gross tumour volume extent during radiotherapy for glioblastomasUffe Bernchou, Trine Skak Tranemose Arnold, Brit Axelsen, et al.
Blood Cancer Journal|July 7, 2023
Potential value of pre-planned imaging of bone disease in multiple myelomaMichael T Gundesen, Jon Thor Asmussen, Fredrik Schjesvold, et al.
Scientific Reports|April 5, 2023
2-[<sup>18</sup>F]FDG-PET/CT is a better predictor of survival than conventional CT: a prospective study of response monitoring in metastatic breast cancerMarianne Vogsen, Mohammad Naghavi-Behzad, Frederik Graae Harbo, et al.
British Journal of Cancer|January 11, 2022
Response monitoring in metastatic breast cancer: a comparison of survival times between FDG-PET/CT and CE-CTMohammad Naghavi-Behzad, Marianne Vogsen, Rasmus Mølgård Vester, et al.
Blood Cancer Journal|April 15, 2024
In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone diseaseThomas Lund, Michael Tveden Gundesen, Annette Juul Vangsted, et al.
Radiology|February 27, 2019
Guidelines for Acquisition, Interpretation, and Reporting of Whole-Body MRI in Myeloma: Myeloma Response Assessment and Diagnosis System (MY-RADS)Christina Messiou, Jens Hillengass, Stefan Delorme, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|March 27, 2023
Increased Bone Volume by Ixazomib in Multiple Myeloma: 3-Month Results from an Open Label Phase 2 StudyMarta Diaz-delCastillo, Michael Tveden Gundesen, Christian Walther Andersen, et al.
Bone|September 25, 2025
Ixazomib treatment has a dual effect on bone remodeling in patients with multiple myeloma: follow-up results from a phase 2 clinical studyMette Bøegh Levring, Marta Diaz-delCastillo, Michael Tveden Gundesen, et al.
BJUI Compass|August 28, 2023
A randomised trial of [<sup>18</sup>F]PSMA-1007-PET/CT versus NaF-PET/CT for staging primary prostate cancer: A trial protocolKaren Middelbo Buch-Olsen, Mads Hvid Poulsen, Steinbjørn Hansen, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 13, 2021
Evolution of the gross tumour volume extent during radiotherapy for glioblastomasUffe Bernchou, Trine Skak Tranemose Arnold, Brit Axelsen, et al.
Blood Cancer Journal|July 7, 2023
Potential value of pre-planned imaging of bone disease in multiple myelomaMichael T Gundesen, Jon Thor Asmussen, Fredrik Schjesvold, et al.
Scientific Reports|April 5, 2023
2-[<sup>18</sup>F]FDG-PET/CT is a better predictor of survival than conventional CT: a prospective study of response monitoring in metastatic breast cancerMarianne Vogsen, Mohammad Naghavi-Behzad, Frederik Graae Harbo, et al.
British Journal of Cancer|January 11, 2022
Response monitoring in metastatic breast cancer: a comparison of survival times between FDG-PET/CT and CE-CTMohammad Naghavi-Behzad, Marianne Vogsen, Rasmus Mølgård Vester, et al.
Blood Cancer Journal|April 15, 2024
In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone diseaseThomas Lund, Michael Tveden Gundesen, Annette Juul Vangsted, et al.
Radiology|February 27, 2019
Guidelines for Acquisition, Interpretation, and Reporting of Whole-Body MRI in Myeloma: Myeloma Response Assessment and Diagnosis System (MY-RADS)Christina Messiou, Jens Hillengass, Stefan Delorme, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|March 27, 2023
Increased Bone Volume by Ixazomib in Multiple Myeloma: 3-Month Results from an Open Label Phase 2 StudyMarta Diaz-delCastillo, Michael Tveden Gundesen, Christian Walther Andersen, et al.
Bone|September 25, 2025
Ixazomib treatment has a dual effect on bone remodeling in patients with multiple myeloma: follow-up results from a phase 2 clinical studyMette Bøegh Levring, Marta Diaz-delCastillo, Michael Tveden Gundesen, et al.
BJUI Compass|August 28, 2023
A randomised trial of [<sup>18</sup>F]PSMA-1007-PET/CT versus NaF-PET/CT for staging primary prostate cancer: A trial protocolKaren Middelbo Buch-Olsen, Mads Hvid Poulsen, Steinbjørn Hansen, et al.
Pageof 2